Skip to main content

Table 2 Antibody distribution in 169 patients with Crohn’s disease (CD), 102 patients with ulcerative colitis (UC), and 225 controls

From: Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn’s disease

  CD UC controls
  All CD patients (n = 169) ASCA negative CD patients (n = 109) (n = 102) (n = 225)
Anti-GP2 IgA, (%) 22 (13.0) 9 (8.2) 2 (2.0) 3 (1.3)
Anti-GP2 IgG, (%) 48 (28.4) 25 (22.9) 8 (7.8) 6 (2.7)
Anti-GP2 IgA and/or IgG, (%) 51 (30.2) 26 (23.9) 9 (8.8) 9 (4.0)
PAB > = 1/20, (%) 74 (43.8) 45 (41.3) 24 (23.5) nd
PAB > = 1/40, (%) 65 (38.5) 38 (34.9) 21 (20.6) nd
ASCA IgA, (%) 39 (23.1) - 3 (2.9) 2 (0.9)
ASCA IgG, (%) 48 (28.4) - 5 (4.9) 7 (3.1)
ASCA IgA and/or IgG, (%) 60 (35.5) - 7 (6.9) 8 (3.5)
ASCA and/or anti-GP2, (%) 86 (50.9) - 15 (14.7) 16 (7.1)
Number of positive antibodies detected by ELISA     
0 83 (49.1) 83 (76.1) 87 (85.3) 208 (92.4)
1 40 (23.7) 18 (16.5) 12 (11.8) 13 (5.8)
2 28 (16.6) 8 (7.3) 3 (2.9) 4 (1.8)
3 11 (6.5) - 0 (0.0) 0 (0.0)
4 7 (4.1) - 0 (0.0) 0 (0.0)
  1. ASCA, antibody to mannan of Saccharomyces cerevisiae; CI, confidence interval; GP2, zymogen granule membrane glycoprotein 2; nd, not done; PAB, pancreatic autoantibody.